A randomized trial of 24- vs. 48-week courses of PEG interferon α-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan
- 18 November 2005
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 26 (1), 73-81
- https://doi.org/10.1111/j.1478-3231.2005.01196.x
Abstract
To assess the efficacy of 24- or 48-week peginterferon/ribavirin treatment of Taiwanese patients with chronic hepatitis C virus genotype-1b (HCV-1b) infection, and to identify subgroups of patients in whom the 48-week treatment has benefits. We assigned 60 patients receiving peginterferon-alpha-2b (80-100 mcg/week) plus ribavirin (1000-1200 mg/day), depending on body weight, for 24 or 48 weeks, with a 3:1 randomization ratio. The sustained virological response (SVR) rate was significantly higher in the 48-week (80.0%, 12/15) than in the 24-week group (48.9%, 22/45, P < 0.05). The 60 patients were classified into two subgroups according to the presence of unfavorable baseline predictors: viral loads > or = 400,000 IU/ml or a hepatic fibrosis score of 3-4. In 19 patients without an unfavorable predictor, the SVR rate was comparable in the 24-week (78.6%) and 48-week (75.0%) groups; in patients with either unfavorable predictors, the SVR rate was significantly higher in the 48-week (81.1%, 9/11) than in the 24-week group (36.7%, 11/30, P = 0.015). The discontinuation rate was significantly higher in the 48-week (20.0%, 3/15) than in the 24-week group (2.2%, 1/45, P < 0.05). A 48-week course of peginterferon-alpha-2b/ribavirin was more effective than a 24-week course in Taiwanese HCV-1b patients, mainly in those with high viral loads and/or advanced hepatic fibrosis.Keywords
This publication has 21 references indexed in Scilit:
- Comparison of a 6‐month course peginterferon α‐2b plus ribavirin and interferon α‐2b plus ribavirin in treating Chinese patients with chronic hepatitis C in TaiwanJournal of Viral Hepatitis, 2005
- A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factorsAntiviral Research, 2004
- Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1Hepatology, 2004
- A 48‐Week Duration of Therapy with Pegylated Interferon α2b plus Ribavirin May Be Too Short to Maximize Long‐Term Response among Patients Infected with Genotype‐1 Hepatitis C VirusThe Journal of Infectious Diseases, 2004
- Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis CHepatology, 2003
- Human Leukocyte Antigen Class I and II Alleles and Response to Interferon?? Treatment, in Taiwanese Patients with Chronic Hepatitis C Virus InfectionThe Journal of Infectious Diseases, 2003
- Racial Differences in HLA Class II Associations with Hepatitis C Virus OutcomesThe Journal of Infectious Diseases, 2001
- Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis CGastroenterology, 1996
- Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detectionJournal of General Virology, 1993
- Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitisHepatology, 1981